Clinical trials: Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
The purpose of this study is to demonstrate the non-inferiority of treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor as per IMDC mRCC patients with a confirmed…
- Trial name
- SPICI (NCT05219318)
- Testing
- Combination PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause
- Where
- 26 sites in France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Bordeaux